Muscle Function Recovery in Golden Retriever Muscular Dystrophy After AAV1-U7 Exon Skipping

Hoffman, 1987, Dystrophin: the protein product of the Duchenne muscular dystrophy locus, Cell, 51, 919, 10.1016/0092-8674(87)90579-4 Chelly, 1988, Transcription of the dystrophin gene in human muscle and non-muscle tissue, Nature, 333, 858, 10.1038/333858a0 Bonilla, 1988, Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface, Cell, 54, 447, 10.1016/0092-8674(88)90065-7 Petrof, 1993, Dystrophin protects the sarcolemma from stresses developed during muscle contraction, Proc Natl Acad Sci USA, 90, 3710, 10.1073/pnas.90.8.3710 Emery, 1993, Duchenne Muscular Dystrophy, 1 Cotton, 2001, Intelligence and Duchenne muscular dystrophy: full-scale, verbal, and performance intelligence quotients, Dev Med Child Neurol, 43, 497, 10.1017/S0012162201000913 Koenig, 1987, Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals, Cell, 50, 509, 10.1016/0092-8674(87)90504-6 Muntoni, 2003, Dystrophin and mutations: one gene, several proteins, multiple phenotypes, Lancet Neurol, 2, 731, 10.1016/S1474-4422(03)00585-4 Matsuo, 1996, Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy, Brain Dev, 18, 167, 10.1016/0387-7604(96)00007-1 Lu, 2011, The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy, Mol Ther, 19, 9, 10.1038/mt.2010.219 Aartsma-Rus, 2010, Antisense-mediated modulation of splicing: therapeutic implications for Duchenne muscular dystrophy, RNA Biol, 7, 453, 10.4161/rna.7.4.12264 Cirak, 2011, Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study, Lancet, 378, 595, 10.1016/S0140-6736(11)60756-3 Cirak, 2011, Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study, Lancet, 378, 595, 10.1016/S0140-6736(11)60756-3 Kinali, 2009, Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study, Lancet Neurol, 8, 918, 10.1016/S1474-4422(09)70211-X van Deutekom, 2007, Local dystrophin restoration with antisense oligonucleotide PRO051, N Engl J Med, 357, 2677, 10.1056/NEJMoa073108 Gorman, 1998, Stable alteration of pre-mRNA splicing patterns by modified U7 small nuclear RNAs, Proc Natl Acad Sci USA, 95, 4929, 10.1073/pnas.95.9.4929 Goyenvalle, 2004, Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping, Science, 306, 1796, 10.1126/science.1104297 Goyenvalle, 2009, Enhanced exon-skipping induced by U7 snRNA carrying a splicing silencer sequence: Promising tool for DMD therapy, Mol Ther, 17, 1234, 10.1038/mt.2009.113 Valentine, 1992, Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: a review, Am J Med Genet, 42, 352, 10.1002/ajmg.1320420320 Sharp, 1992, An error in dystrophin mRNA processing in golden retriever muscular dystrophy, an animal homologue of Duchenne muscular dystrophy, Genomics, 13, 115, 10.1016/0888-7543(92)90210-J Barbash, 2012, MRI roadmap-guided transendocardial delivery of exon-skipping recombinant adeno-associated virus restores dystrophin expression in a canine model of Duchenne muscular dystrophy, Gene Ther Bish, 2012, Long-term restoration of cardiac dystrophin expression in golden retriever muscular dystrophy following rAAV6-mediated exon skipping, Mol Ther, 20, 580, 10.1038/mt.2011.264 Yokota, 2009, Efficacy of systemic morpholino exon-skipping in Duchenne dystrophy dogs, Ann Neurol, 65, 667, 10.1002/ana.21627 Schatzberg, 1998, Alternative dystrophin gene transcripts in golden retriever muscular dystrophy, Muscle Nerve, 21, 991, 10.1002/(SICI)1097-4598(199808)21:8<991::AID-MUS2>3.0.CO;2-0 McClorey, 2006, Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD, Gene Ther, 13, 1373, 10.1038/sj.gt.3302800 Blake, 1996, Utrophin: a structural and functional comparison to dystrophin, Brain Pathol, 6, 37, 10.1111/j.1750-3639.1996.tb00781.x Valentine, 1989, Intracellular calcium in canine muscle biopsies, J Comp Pathol, 100, 223, 10.1016/0021-9975(89)90099-6 Thibaud, 2007, Characterization of dystrophic muscle in golden retriever muscular dystrophy dogs by nuclear magnetic resonance imaging, Neuromuscul Disord, 17, 575, 10.1016/j.nmd.2007.03.013 Kornegay, 1999, Contraction force generated by tarsal joint flexion and extension in dogs with golden retriever muscular dystrophy, J Neurol Sci, 166, 115, 10.1016/S0022-510X(99)00118-5 Deconinck, 1997, Expression of truncated utrophin leads to major functional improvements in dystrophin-deficient muscles of mice, Nat Med, 3, 1216, 10.1038/nm1197-1216 Goyenvalle, 2012, Rescue of severely affected dystrophin/utrophin-deficient mice through scAAV-U7snRNA-mediated exon skipping, Hum Mol Genet, 21, 2559, 10.1093/hmg/dds082 Schümperli, 2004, The special Sm core structure of the U7 snRNP: far-reaching significance of a small nuclear ribonucleoprotein, Cell Mol Life Sci, 61, 2560, 10.1007/s00018-004-4190-0 Clerk, 1993, Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle, Histochem J, 25, 554, 10.1007/BF02388063 Beggs, 1991, Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies, Am J Hum Genet, 49, 54 Banks, 2007, Functional capacity of dystrophins carrying deletions in the N-terminal actin-binding domain, Hum Mol Genet, 16, 2105, 10.1093/hmg/ddm158 Manno, 2003, AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B, Blood, 101, 2963, 10.1182/blood-2002-10-3296 Chenuaud, 2004, Optimal design of a single recombinant adeno-associated virus derived from serotypes 1 and 2 to achieve more tightly regulated transgene expression from nonhuman primate muscle, Mol Ther, 9, 410, 10.1016/j.ymthe.2003.12.015 Rivera, 2005, Long-term pharmacologically regulated expression of erythropoietin in primates following AAV-mediated gene transfer, Blood, 105, 1424, 10.1182/blood-2004-06-2501 Herzog, 1997, Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus, Proc Natl Acad Sci USA, 94, 5804, 10.1073/pnas.94.11.5804 Wang, 2007, Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy, Hum Gene Ther, 18, 18, 10.1089/hum.2006.093 Wang, 2011, Immunity and AAV-Mediated Gene Therapy for Muscular Dystrophies in Large Animal Models and Human Trials, Front Microbiol, 2, 201, 10.3389/fmicb.2011.00201 Mendell, 2010, Sustained alpha-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D, Ann Neurol, 68, 629, 10.1002/ana.22251 Herson, 2012, A phase I trial of adeno-associated virus serotype 1-?-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C, Brain, 135, 483, 10.1093/brain/awr342 Mingozzi, 2009, AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells, Blood, 114, 2077, 10.1182/blood-2008-07-167510 Bowles, 2012, Phase 1 gene therapy for Duchenne muscular dystrophy using a translational optimized AAV vector, Mol Ther, 20, 443, 10.1038/mt.2011.237 Mendell, 2010, Dystrophin immunity in Duchenne's muscular dystrophy, N Engl J Med, 363, 1429, 10.1056/NEJMoa1000228 Lorain, 2008, Transient immunomodulation allows repeated injections of AAV1 and correction of muscular dystrophy in multiple muscles, Mol Ther, 16, 541, 10.1038/sj.mt.6300377 Kornegay, 2010, Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs, Mol Ther, 18, 1501, 10.1038/mt.2010.94 Romero, 2004, Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy, Hum Gene Ther, 15, 1065, 10.1089/hum.2004.15.1065 Hagstrom, 2004, A facile nonviral method for delivering genes and siRNAs to skeletal muscle of mammalian limbs, Mol Ther, 10, 386, 10.1016/j.ymthe.2004.05.004 Thibaud, 2006, Intravascular administration of dystrophin plasmid DNA in a canine model of Duchenne Muscular Dsytrophy: early side effects and long term biological efficacy, J Vet Intern Med, 20, 1270 Sampaolesi, 2006, Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs, Nature, 444, 574, 10.1038/nature05282